Peterlabs Holdings Bhd's Days Sales Outstanding for the
three
months ended in Jun. 2025 was 72.25.
Peterlabs Holdings Bhd's Days Inventory for the
three
months ended in Jun. 2025 was 74.49.
Peterlabs Holdings Bhd's Days Payable for the
three
months ended in Jun. 2025 was 28.29.
Therefore, Peterlabs Holdings Bhd's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2025 was 118.45.
Peterlabs Holdings Bhd (XKLS:0171) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Peterlabs Holdings Bhd Cash Conversion Cycle Related Terms
Peterlabs Holdings Bhd Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Peterlabs Holdings Bhd's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd Cash Conversion Cycle Chart
XKLS:0171 vs ZTS, UTHR, VTRS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's Cash Conversion Cycle falls into.
Peterlabs Holdings Bhd Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Peterlabs Holdings Bhd's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd (XKLS:0171) has a Cash Conversion Cycle of 118.45 as of Jun. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Peterlabs Holdings Bhd and its competitors.
Is Peterlabs Holdings Bhd's Cash Conversion Cycle too high?
Peterlabs Holdings Bhd's current Cash Conversion Cycle is 118.45. The Drug Manufacturers industry median Cash Conversion Cycle is 145.87. Peterlabs Holdings Bhd's value of 118.45 is 18.8% below this industry median. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's Cash Conversion Cycle compare to ZTS and UTHR?
Peterlabs Holdings Bhd's Cash Conversion Cycle of 118.45 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.87. Peterlabs Holdings Bhd's value of 118.45 is 18.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.87, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peterlabs Holdings Bhd's current Cash Conversion Cycle of 118.45 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current Cash Conversion Cycle is 118.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd (XKLS:0171) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.20, compared to a current price of RM0.24 — trading 20% above its estimated fair value. The current Cash Conversion Cycle is 118.45 and 18.8% below the Drug Manufacturers industry median of 145.87. Peterlabs Holdings Bhd's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current Cash Conversion Cycle is 118.45 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peterlabs Holdings Bhd (XKLS:0171) Overvalued in 2026?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd stock appears to be overvalued.
The current stock price of RM0.24 is trading 20% above its estimated GF Value™ of RM0.20.
GuruFocus considers Peterlabs Holdings Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0171:
Cash Conversion Cycle: 118.45
GF Value™: RM0.20 vs. price of RM0.24 (20% above fair value)
Industry Position: 18.8% below the Drug Manufacturers median
No single metric tells the full story. See the XKLS:0171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
